Literature DB >> 20004891

Development of new glycosylation methodologies for the synthesis of archaeal-derived glycolipid adjuvants.

Dennis M Whitfield1, Siu H Yu, Chantale J Dicaire, G Dennis Sprott.   

Abstract

To commercialize the production of glycolipid adjuvants, their synthesis needs to be both robust and inexpensive. Herein we describe a semi-synthetic approach where the lipid acceptor is derived from the biomass of the archaeon Halobacterium salinarum, and the glycosyl donors are chemically synthesized. This work presents some preliminary results using the promoter system N-iodosuccinimide (NIS) and a stable 0.25 M solution of boron trifluoride-trifluoroethanol (BF(3) x TFE(2)) in dichloromethane. This promoter system allows for the use of peracetyl alkyl(aryl)thioglycosides that are available in high yield from inexpensive disaccharide starting materials by promoting clean glycosylation reactions from which pure product can be easily isolated. Conventional glycosylation using NIS-silver trifluoromethanesulfonate (AgOTf) leads to extensive acetyl transfer to the archaeol acceptor and numerous byproducts that make purification complicated. As part of preliminary structure-adjuvant activity studies, we describe the one-pot synthesis of a gentiobiose beta-Glcp-(1-->6)-Glcp-SEt donor with an O-2 benzoyl group, which can be used to prepare a disaccharide attached to archaeol in 85% overall yield, and the related glycolipid trisaccharide beta-Glcp-(1-->6)-beta-Glcp-(1-->6)-beta-Glcp-(1-->O)-archaeol. The synthesis of the isomeric beta-Glcp-(1-->6)-alpha-Glcp-(1-->O)-archaeol featuring a >10:1 alpha/beta alpha-selective glycosylation using the promoter system N-phenylselenylphthalimide-trifluoromethanesulfonic acid (TfOH) is also presented, along with the adjuvant properties of the corresponding archaeosomes (liposomes comprised entirely of combinations of isoprenoid archaeal-like lipids). These new vaccine formulations extend previous observations that glycolipids are integral to the activation of MHC type I pathways via CD8(+) antigen-specific T-cells. The beta-Glcp-(1-->6)-beta-Glcp-(1-->6)-beta-Glcp-(1-->O)-archaeol trisaccharide is shown to be more active than the Glcp-(1-->6)-beta-Glcp-(1-->O)-archaeol disaccharide. 2009. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20004891     DOI: 10.1016/j.carres.2009.10.011

Source DB:  PubMed          Journal:  Carbohydr Res        ISSN: 0008-6215            Impact factor:   2.104


  6 in total

1.  Safety and biodistribution of sulfated archaeal glycolipid archaeosomes as vaccine adjuvants.

Authors:  Bassel Akache; Felicity C Stark; Umar Iqbal; Wangxue Chen; Yimei Jia; Lakshmi Krishnan; Michael J McCluskie
Journal:  Hum Vaccin Immunother       Date:  2018-01-30       Impact factor: 3.452

2.  Synthetic archaeosome vaccines containing triglycosylarchaeols can provide additive and long-lasting immune responses that are enhanced by archaetidylserine.

Authors:  G Dennis Sprott; Angela Yeung; Chantal J Dicaire; Siu H Yu; Dennis M Whitfield
Journal:  Archaea       Date:  2012-09-30       Impact factor: 3.273

Review 3.  Biosynthesis of archaeal membrane ether lipids.

Authors:  Samta Jain; Antonella Caforio; Arnold J M Driessen
Journal:  Front Microbiol       Date:  2014-11-26       Impact factor: 5.640

4.  Sulfated archaeal glycolipid archaeosomes as a safe and effective vaccine adjuvant for induction of cell-mediated immunity.

Authors:  Michael J McCluskie; Lise Deschatelets; Lakshmi Krishnan
Journal:  Hum Vaccin Immunother       Date:  2017-05-24       Impact factor: 3.452

5.  Sulfated archaeol glycolipids: Comparison with other immunological adjuvants in mice.

Authors:  Bassel Akache; Felicity C Stark; Yimei Jia; Lise Deschatelets; Renu Dudani; Blair A Harrison; Gerard Agbayani; Dean Williams; Mohammad P Jamshidi; Lakshmi Krishnan; Michael J McCluskie
Journal:  PLoS One       Date:  2018-12-04       Impact factor: 3.240

6.  Simplified Admix Archaeal Glycolipid Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Enhances Protection from Murine Melanoma.

Authors:  Felicity C Stark; Gerard Agbayani; Jagdeep K Sandhu; Bassel Akache; Charis McPherson; Lise Deschatelets; Renu Dudani; Melissa Hewitt; Yimei Jia; Lakshmi Krishnan; Michael J McCluskie
Journal:  Biomedicines       Date:  2019-11-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.